GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nextbiomedical Co Ltd (XKRX:389650) » Definitions » Interest Coverage

Nextbiomedical Co (XKRX:389650) Interest Coverage : 0 (At Loss) (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Nextbiomedical Co Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Nextbiomedical Co's Operating Income for the three months ended in Mar. 2025 was ₩-668 Mil. Nextbiomedical Co's Interest Expense for the three months ended in Mar. 2025 was ₩-112 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Nextbiomedical Co's Interest Coverage or its related term are showing as below:


XKRX:389650's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Nextbiomedical Co Interest Coverage Historical Data

The historical data trend for Nextbiomedical Co's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nextbiomedical Co Interest Coverage Chart

Nextbiomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
- - - - -

Nextbiomedical Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nextbiomedical Co's Interest Coverage

For the Biotechnology subindustry, Nextbiomedical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nextbiomedical Co's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nextbiomedical Co's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Nextbiomedical Co's Interest Coverage falls into.


;
;

Nextbiomedical Co Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nextbiomedical Co's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Nextbiomedical Co's Interest Expense was ₩-520 Mil. Its Operating Income was ₩-3,575 Mil. And its Long-Term Debt & Capital Lease Obligation was ₩784 Mil.

Nextbiomedical Co did not have earnings to cover the interest expense.

Nextbiomedical Co's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Nextbiomedical Co's Interest Expense was ₩-112 Mil. Its Operating Income was ₩-668 Mil. And its Long-Term Debt & Capital Lease Obligation was ₩738 Mil.

Nextbiomedical Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Nextbiomedical Co  (XKRX:389650) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Nextbiomedical Co Interest Coverage Related Terms

Thank you for viewing the detailed overview of Nextbiomedical Co's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Nextbiomedical Co Business Description

Traded in Other Exchanges
N/A
Address
Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.

Nextbiomedical Co Headlines

No Headlines